Is Tesla Going to Buy Uber?
Tesla has always been in the habit of making large,…
Sell
35
PHVS Quote, Financials, Valuation and Earnings
Last price:
$18.95
Seasonality move
:
3.9%
Day range:
$18.82 - $19.93
52-week range:
$15.37 - $33.00
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
3.10x
Volume:
26K
Avg. volume:
85.4K
1-year change:
-29.68%
Market cap:
$1B
Revenue:
--
EPS (TTM):
-$2.82
Analysts' Opinion
-
Consensus RatingPharvaris NV has received a consensus rating of Buy. The company's average rating is a Buy based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of --, Pharvaris NV has an estimated upside of 82.64% from its current price of $18.93.
-
Price Target DownsideAccording to analysts, the lowest downside price target is -- representing 100% downside risk from its current price of $18.93.
Fair Value
-
According to the consensus of 0 analysts, Pharvaris NV has 82.64% upside to fair value with a price target of -- per share.
PHVS vs. S&P 500
-
Over the past 5 trading days, Pharvaris NV has overperformed the S&P 500 by 0.58% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Pharvaris NV does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Pharvaris NV has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Pharvaris NV reported revenues of --.
Earnings Growth
-
Pharvaris NV has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Pharvaris NV reported earnings per share of -$0.85.
Enterprise value:
685.8M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
-5.74x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$85.6M | -$99.7M | -$138.7M | -$28.5M | -$41.7M | |
| EBITDA | -$79M | -$126.6M | -$138.5M | -$28.5M | -$41.6M | |
| Diluted EPS | -$1.61 | -$3.12 | -$2.82 | -$0.63 | -$0.85 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $50.5M | $258.2M | $198.9M | $178.4M | $348.8M | |
| Total Assets | $50.5M | $258.8M | $199.5M | $179.2M | $349.8M | |
| Current Liabilities | $5.1M | $8.7M | $17.4M | $17.1M | $18.3M | |
| Total Liabilities | $5.1M | $8.9M | $17.5M | $17.2M | $18.3M | |
| Total Equity | $45.4M | $249.9M | $182M | $162.1M | $331.5M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$62M | -$99.1M | -$119M | -$25.6M | -$37.8M | |
| Cash From Investing | -$182.7K | -$96.8K | -$445.2K | -$8.1K | -$338.5K | |
| Cash From Financing | $8.7M | $69.6M | $285.3M | -$238.5K | $1.1M | |
| Free Cash Flow | -$62.2M | -$99.2M | -$119.5M | -$25.6M | -$38.1M | |
PHVS
Sector
Market Cap
$1B
$45.6M
Price % of 52-Week High
57.36%
45.55%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.74%
1-Year Price Total Return
-29.68%
-31.35%
Beta (5-Year)
--
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$18.86
200-day SMA
Sell
Level
$20.04
Bollinger Bands (100)
Sell
Level
17.74 - 21.94
Chaikin Money Flow
Buy
Level
57.6M
20-day SMA
Sell
Level
$19.84
Relative Strength Index (RSI14)
Sell
Level
44.12
ADX Line
Buy
Level
19.93
Williams %R
Neutral
Level
-61.4583
50-day SMA
Sell
Level
$21.15
MACD (12, 26)
Sell
Level
-0.62
25-day Aroon Oscillator
Sell
Level
-36
On Balance Volume
Neutral
Level
78.1M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (8)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Pharvaris NV is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.
Stock Forecast FAQ
In the current month, PHVS has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The PHVS average analyst price target in the past 3 months is --.
-
Where Will Pharvaris NV Stock Be In 1 Year?
According to analysts, the consensus estimate is that Pharvaris NV share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Pharvaris NV?
Analysts are divided on their view about Pharvaris NV share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Pharvaris NV is a Sell and believe this share price will drop from its current level to --.
-
What Is Pharvaris NV's Price Target?
The price target for Pharvaris NV over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is PHVS A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Pharvaris NV is a Buy. 0 of 0 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of PHVS?
You can purchase shares of Pharvaris NV via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Pharvaris NV shares.
-
What Is The Pharvaris NV Share Price Today?
Pharvaris NV was last trading at $18.95 per share. This represents the most recent stock quote for Pharvaris NV. Yesterday, Pharvaris NV closed at $18.93 per share.
-
How To Buy Pharvaris NV Stock Online?
In order to purchase Pharvaris NV stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
NVIDIA vs Broadcom Stock: Which Is Best?
If you want to invest in an AI-leading tech company,…
Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 117x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Sell
40
MSTR alert for Dec 24
MicroStrategy [MSTR] is down 8.7% over the past day.
Sell
26
NUTX alert for Dec 24
Nutex Health [NUTX] is up 9.77% over the past day.
Sell
48
VRNA alert for Dec 24
Verona Pharma PLC [VRNA] is up 7.96% over the past day.
